Arca Biopharma (ABIO) 0.70 $ABIO
ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of Gencaro
Business Wire - Wed Feb 04, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods and compositions of the S-isomer formulation of Gencaro(TM) (bucindolol hydrochloride). The patent (USP# 8946284), entitled "Methods and Compositions involving (S)-Bucindolol," provides intellectual property protection in the United States for the use of S-isomer Gencaro (Gencaro substantially free of its R-stereoisomer) as a potential treatment for right ventricular heart failure, congestive heart failure, hypertension, angina, myocardial infarction, cardiac arrhythmia, mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm.
ABIO: 0.70 (+0.03)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), TKMR: 21.45 (-0.22), ABIO: 0.70 (+0.03)
Arca continues Orphan Drug-stoked up move
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 10:21AM CST
ABIO: 0.70 (+0.03)
Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site
Business Wire - Thu Dec 11, 7:30AM CST
--Approximately 60 Trial Sites Planned in the United States and Canada
ABIO: 0.70 (+0.03)
Arca TF inhibitor an Orphan Drug for hemorrhagic fever
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:14AM CST
ABIO: 0.70 (+0.03)
ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola
Business Wire - Wed Dec 10, 7:30AM CST
--rNAPc2 Previously Tested in Over 700 Human Patients in Nine Phase 1 and 2 Cardiovascular Disease Clinical Trials
ABIO: 0.70 (+0.03)
ARCA's CFO leaving; COO appointed
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 5:11PM CST
ABIO: 0.70 (+0.03)
ARCA biopharma Announces Management Transitions
Business Wire - Mon Dec 01, 4:00PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.
ABIO: 0.70 (+0.03)
LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Tue Sep 16, 7:01AM CDT
ARCA biopharma, Inc. (ARCA) (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract was presented yesterday evening at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 116.90 (+0.06), ABIO: 0.70 (+0.03)
LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Mon Sep 08, 7:30AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract has been accepted for moderated poster presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 116.90 (+0.06), ABIO: 0.70 (+0.03)
ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application
Business Wire - Mon Aug 18, 7:30AM CDT
--Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ABIO: 0.70 (+0.03)
ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of Gencaro
Business Wire - Wed Feb 04, 7:30AM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods and compositions of the S-isomer formulation of Gencaro(TM) (bucindolol hydrochloride). The patent (USP# 8946284), entitled "Methods and Compositions involving (S)-Bucindolol," provides intellectual property protection in the United States for the use of S-isomer Gencaro (Gencaro substantially free of its R-stereoisomer) as a potential treatment for right ventricular heart failure, congestive heart failure, hypertension, angina, myocardial infarction, cardiac arrhythmia, mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm.
ABIO: 0.70 (+0.03)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
NanoViricides up on report of Ebola drug progress
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 11:12AM CST
INO: 6.80 (-0.15), BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), ABIO: 0.70 (+0.03), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05)
BioCryst starts Phase 1 trial for hemorrhagic fever treatment
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:02AM CST
BCRX: 10.06 (-0.09), CMRX: 40.16 (+0.08), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), TKMR: 21.45 (-0.22), ABIO: 0.70 (+0.03)
Arca continues Orphan Drug-stoked up move
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 10:21AM CST
ABIO: 0.70 (+0.03)
Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site
Business Wire - Thu Dec 11, 7:30AM CST
--Approximately 60 Trial Sites Planned in the United States and Canada
ABIO: 0.70 (+0.03)
Arca TF inhibitor an Orphan Drug for hemorrhagic fever
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 9:14AM CST
ABIO: 0.70 (+0.03)
ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola
Business Wire - Wed Dec 10, 7:30AM CST
--rNAPc2 Previously Tested in Over 700 Human Patients in Nine Phase 1 and 2 Cardiovascular Disease Clinical Trials
ABIO: 0.70 (+0.03)
ARCA's CFO leaving; COO appointed
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 5:11PM CST
ABIO: 0.70 (+0.03)
ARCA biopharma Announces Management Transitions
Business Wire - Mon Dec 01, 4:00PM CST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions.
ABIO: 0.70 (+0.03)
LabCorp/ARCA biopharma GENETIC-AF Poster Presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Tue Sep 16, 7:01AM CDT
ARCA biopharma, Inc. (ARCA) (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract was presented yesterday evening at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 116.90 (+0.06), ABIO: 0.70 (+0.03)
LabCorp/ARCA biopharma GENETIC-AF Poster Selected for Presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America
Business Wire - Mon Sep 08, 7:30AM CDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that a joint Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) and ARCA personalized medicine abstract has been accepted for moderated poster presentation at the 18th Annual Scientific Meeting of the Heart Failure Society of America, being held September 14-17, 2014 in Las Vegas, Nevada. The poster describes the genetic test that is being used to select patients for GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which ARCA believes is present in approximately 50% of the U.S. population. LabCorp is performing the genetic testing for the GENETIC-AF trial.
LH: 116.90 (+0.06), ABIO: 0.70 (+0.03)
ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application
Business Wire - Mon Aug 18, 7:30AM CDT
--Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment
ABIO: 0.70 (+0.03)
